Olivier NATAF

In 2001, Olivier began his career at AstraZeneca where he held various positions in several therapeutic areas (Oncology, Hematology, Urology, Neurosciences, and Cardiovascular Renal and Metabolism) which allowed him to acquire a global vision but also a deep insight in the challenges of the patient journey. He has been responsible for the OBU in France, where he has enabled major therapeutic innovations as well as important initiatives to strengthen the diagnosis of these pathologies. He also held the position of International Oncology Sales Director with responsibilities in Asia, Russia, Australia, Latin America, Middle East and Africa.

Before being appointed President France at the end of 2019, Olivier Nataf headed AstraZeneca's Oncology Business Unit in the United States, where he significantly contributed to developing this market. He also helped establish the collaborations with Merck, Innate Pharma and Daiichi- Sankyo for the entire Group. A scientist by training, he has a solid international and transverse experience to support AstraZeneca in France.

Since his arrival in November 2019, Olivier has been committed in health innovation with a strong holistic vision by inviting to a public-private collaboration. He made it possible to establish AstraZeneca's Innovation Hub in Paris and to pursue the development of new patient solutions. He contributed to the involvement of AstraZeneca to “L’Alliance Digitale Contre le COVID-19”. He is co-Founder of “Coalition Innovation Santé” alongside France Digitale, France Biotech and MedTech in France with the support of AP-HP, Bpifrance, EIT Health.
He represents AstraZeneca in associations of pharmaceutical companies (Acting President of the LEEM, and president of its "industrial transformation" commission) as well as in the field of Healthcare innovation (President of Innovation100T France).

Olivier Nataf graduated in molecular biology from Pierre et Marie Curie University and from the University of Chicago also holds a MS in Pharmaco-Oncology from the École Normale supérieure, and a MS from École Supérieure de Commerce in Paris (ESCP) and a Master from The French Institute for International and Strategic Affairs (IRIS).